Introduction
Lung cancer is the most common cancer in the world and represents the most common cause of death from cancer worldwide [1] . Approximately 85% of all lung cancer cases are non-small cell type (NSCLC) and traditionally the treatment of this category of lung cancer was limited to radiotherapy, chemotherapy, or a combination of both [2] . Although much progress has been recently made for lung cancer such as molecularly targeted therapies, patients with lung cancer are still facing a relatively low 5-year survival rate at 17.4% [3, 4] . Recent approaches to NSCLC management has focused on targeting immune checkpoint inhibitors.
Programmed death 1 (PD-1), a member of the CD28 family, is a key immune checkpoint receptor expressing on the surface of the activate T, B and natural killer (NK) cells and plays a crucial role in tumour immune escape [3] .
Programmed death ligand 1 (PD-L1), is upregulated in different types of tumours, including NSCLC [3, 5] . PD-L1 binds to PD-1 to reduce the immune response by inducing T-cell apoptosis or exhaustion [3] . Efforts to use monoclonal antibodies (mAbs) to target and block these immunoinhibitory interactions have led to a new era of immunotherapy-based agents for cancer therapy [6, 7] . Current data show that patient outcomes are generally better with these therapies when there is an increase in PD-L1 expression as measured by IHC [2] .
Challenge 1: Multiple PD-L1 Biomarkers for multiple therapies. PD-L1 is unique to other biomarkers in that at least four different therapies for NSCLC have been developed or are in the development phase targeting PD-1/PD-L1, and have been clinically validated with four different companion or complementary PD-L1 immunohistochemistry (IHC) assays to determine patient eligibility and likelihood of response to their respective therapies [8] . Any of the fully human anti-PD1 mAb BMS-936558 (Nivolumab), the humanised anti-PD-1 antibody MK-3945 (Pembrolizumab) and anti-PD-L1 mAbs Atezolizumab and Durvalumab [6] immune checkpoint inhibitor drugs could potentially be applied as patient treatment by oncologists. Although Atezolizumab is not commercially available, IHC interpretation is complicated by the fact that different clones of mAbs raised against the same protein will be specific for different protein epitopes.
Consequently, one PD-L1 IHC test may not necessarily perform in the same way as another [2] . Biomarker studies conducted in the trials of Nivolumab used the anti-PDL1 IHC antibody clone 28-8 (Dako, Glostrup, Denmark). Alternatively, Pembrolizumab studies used a different anti-PD-L1 Dako clone, 22C3. Durvalumab and Atezolizumab had complementary diagnostic tests based on different clones of anti-PD-L1 -Ventana SP263 and SP142 (Tucson, Arizona), respectively [2] . Challenge 2: Different scoring systems. These clones use different scoring systems and have different cut-off thresholds for defining positivity for the application of each drug. In Nivolumab trials, tumour cell staining for PD-L1 was assessed using different thresholds (≥1%, ≥5% and ≥10%) to define positive staining [2, 9] . Pembrolizumab trials considered two 'positive' thresholds of tumour cell staining (≥1% and ≥50%) and the published data support the use of a threshold of 50% or greater for clinical use [2, 10] . Alternatively, the positive threshold for Durvalumab was defined as tumour cell staining of 25% or greater [11] and Atezolizumab is even more detailed with an assessment of both tumour cells and/or tumourassociated immune cells required using the SP142 clone. For tumour cells, four different grades of staining have been considered in clinical trials, defined around cut points of 1%, 5% and 50% tumour cell staining. Immune cell staining is defined with cut-offs at 1%, 5% and 10% [2, 12] . The possibility of a choice of four different drugs and four different approaches to PD-L1 IHC testing would bring significant challenges to oncologists, laboratories performing IHC testing and pathologists interpreting the complementary or companion diagnostic test. To add to the complications surrounding PD-L1 IHC testing, many laboratories may have been employing LDTs if the assay-specific platform was not available or to save money on testing. Consequently, it became important for external quality assurance (EQA) of pathology providers to ensure that both technical and interpretation aspects of this testing were being performed satisfactorily and to devise a method to incorporate the complications surrounding the variables of testing within the program.
One important initiative that commenced at the Royal College of Pathologists of Australasia Quality Assurance Program (RCPAQAP) in 2017 was the collaboration with United Kingdom National External Quality Assessment Scheme (UK NEQAS) Immunocytochemistry (ICC) and
In-Situ Hybridization (ISH) for this challenging implementation of a PD-L1 IHC proficiency testing program for NSCLC.
Challenge 3: Participation.
An RCPAQAP participant survey in 2016 showed that only eight laboratories were performing PD-L1 testing. It would not be viable or meaningful to establish an external quality assurance (EQA) program for only eight participants with the possibility of as many variations in method submissions. UK NEQAS were also at the beginnings of establishing their own program and so the aim of the collaboration with UK NEQAS was to increase the sample size of the pre-pilot program to provide meaningful results and establish a set of guidelines to help harmonise the assessment process. Thirteen Australian laboratories were included in the UK NEQAS prepilot in early 2017, which attracted a total of 47 participants. This increased number of combined participants allowed for a meaningful comparison of results between submissions.
Methods
Pre-pilot participants were provided unstained formalin-fixed, paraffin-embedded (FFPE) tissue sections from two different multi-blocks (1 and 2).
The block was a combination of cell lines, tonsil and NSCLC tissue (A-H) as shown in Figure 1 .
Participants were also asked to submit their methodology with the returned stained slides. The assessment panel included sixteen expert pathologists and scientists.
The pre-assessment meeting included discussions on how to approach the various complications of PD-L1. Outcomes of the discussion included: (a) scoring each individual core/section based on the tumour proportion score (TPS) regardless of intensity and (b) immune cells would only be counted when assessing the SP142 assay, but most importantly, (c) a method to harmonise the clinical cut-offs for positivity was established.
Challenge 4:
Varying clinical cut-offs for positivity. Rather than assessing each clone according to the various clinical cut-offs, a harmonised approach was established which could be used during the assessment of all clones. The TPS was categorised using a series of bins (Table  1) which were set at a TPS range that allowed for assessment of specificity of the result submitted. The TPS was then applied to each core/section on the gold standard for each commercial assay ( Challenge 5: Applying a baseline comparator. To create the gold standards, each block and at every 25th serial level, sections were stained by the manufacturers of the Dako/Agilent 22C3 and 28-8 and the Ventana/Roche SP263 and SP142 approved PD-L1 assays. These 'Golds' were then used as a baseline to compare participant results.
Assessment
The pre-pilot assessment consisted of two groups of assessors, each consisting of at least one PD-L1 specialist pathologist trained in interpretation of PD-L1 assays. Each section/core was assessed on: TPS bin category applied to Gold sections (a) Bin category for each test core/section matching the corresponding gold bin category and (b) technical quality. Opinions were given and a consensus score out of 5 was provided against the scoring criteria described in Table 2 . The UK NEQAS distributed tonsil control tissue (sample E) was assessed as either acceptable, borderline or unacceptable.
Challenge 6: Laboratory Developed Tests (LDTs). It was expected that submissions would include LDTs as they are generally less expensive than the commercial assay. The challenge during the assessment was that there is no standardisation or clear gold standard comparator for LDTs (inhouse in vitro diagnostic medical devices-IVDs), apart from the commercial kits themselves. Proficiency testing becomes extremely important in this scenario to provide oversight and promote high quality and consistent PD-L1 IHC results across antibodies and test platforms and in a variety of settings. The gold standard slides for each of the commercial assays were also used to compare LDT results. Table 2 SCORE PD-L1 DEMONSTRATION 4-5
Good/Excellent demonstration of PD-L1
3 Acceptable demonstration -slightly weak/strong staining; some of the required components may be missing of there may be non-specific/inappropriate staining present.
1-2
Failure to demonstrate the required PD-L1 components
Results
A breakdown of pass rates and methodologies are summarised in Table 3 and Figure 3 . The shaded cells in Table 3 represent the commercial assays and the white cells represent the various LDT methods submitted for assessment. Twenty out of 47 participants submitted an LDT stained slide for the pre-pilot. Figure 6 (6A, 6B) where the patient may not have been offered first-line therapy with Pembrolizumab. Generally, it was noted that tonsil was a preferred control over placenta to show varying levels of PD-L1. Acceptable tonsil staining should show moderate-to-strong PD-L1 staining in crypt epithelial cells and diffuse staining in the germinal centres. The pre-pilot was followed by a pilot (Run 119) in the latter part of 2017.
Challenge 7: Donation of tissue. IHC EQA providers rely on the donation of tissues from participants and advisory committees. Due to the lack of tissue, only the five Australian participants with an unsatisfactory assessment in the pre-pilot were invited to participate in the pilot plus two new laboratories who are regular donors to the RCPAQAP programs. A general improvement was seen between the pre-pilot and pilot results, with the exception of the E1L3N clone (Figure 7 ).
Challenge 8: Interchangeability of clones. The
Blueprint Phase 2 project [13] , verified that Dako 28-8/22C3 and Ventana SP263 show very similar levels of PD-L1 expression on tumour cells suggesting the interchangeability of these three assays. In contradiction, UK NEQAS found that in run 119, differences in PD-L1 expression were seen for cell lines F and G when applying the TPS to the gold standard slides. This was an unexpected challenge and added a new dimension to the assessment. In this scenario, it became extremely important that participants submit the appropriate methodology with the slide submission to be assessed against the correct assay.
The Australian pre-pilot and pilot results are compared in Table 4 . Two out of the three participants who indicated no change to their protocol for the pilot continued to receive a score of 2 for the pilot. One participant who changed from the 22C3 LDT method to the SP263 commercial assay achieved an improvement in score from 2 to 4. One participant switched from a 22C3 LDT in the pre-pilot to an SP263 LDT in the pilot and did not show an improvement in score. It is noted that other EQA schemes have also shown that the commercial assays generally performed better than LDTs, but also that improvement is evident between surveys. Nordic Immunohistochemistry Quality Control (NordiQC) results in Run C1 2017 [14] showed a pass rate of 80% for approved assays and 20% for LDTs. In Run C2 2018 [15] , the pass rate improved in both categories showing a pass rate of 95% for approved assays and 73% for LDTs. NordiQC also showed a preference for tonsil as a control over placenta. [16] . A pilot for this educational portal is expected in 2018. 
Conclusions
There are multiple challenges in implementing a PD-L1 for NSCLC proficiency testing program, which are being experienced in EQA programs around the world [8, 14, 15, 17] . The collaboration of RCPAQAP with UK NEQAS has been successful in providing meaningful results and recommendations to Australian laboratories in PD-L1 for non-small cell lung carcinoma, where participation rates were expected to be low. The pre-pilot PD-L1 meeting at UK NEQAS was successful in establishing assessment guidelines for PD-L1 assessment in NSCLC. Findings suggested that use of a clinically validated PD-L1 immunohistochemistry (IHC) assay performs better during assessment than adopting an LDT. However, devising and validating an optimal method against the clinical assay associated with the PD-1/PD-L1 therapy offered and continual verification of the test can produce the expected results [8] . Following the pre-pilot, it was recommended by UK NEQAS that an optimal inhouse control for participants should include a dynamic range of PD-L1 expression on NSCLC in addition to a sample of tonsil [8] . Tonsil was preferred over placenta to portray varying levels of PD-L1 in normal tissue. RCPAQAP continues to collaborate with UK NEQAS and a technical EQA program for PD-L1 in NSCLC is now available for enrolment. The formation of IQNPath also proves the importance of collaboration between EQA professionals and industry to exchange expertise, ideas and promote interaction.
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